AZD0780, a New Oral PCSK9 Inhibitor, Shows Strong LDL-C Lowering Effects in Phase IIb PURSUIT Study AZD0780, a once-daily oral PCSK9...

Novartis has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Vanrafia ( atrasentan), a highly...